Published finding — does the expert body still believe it?
Grade 3 or 4 adverse events, including pneumonia, occur at similar rates in durvalumab-treated (29.9%) and placebo-treated (26.1%) stage III NSCLC patients receiving consolidation therapy after chemoradiotherapy.
TL;DR · AI-generated
Progression‐free survival was significantly longer with durvalumab than with placebo, and safety was similar between the groups, and the secondary end points also favored durvalsumab.
Author-implied confidence
78%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
90% → 90% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
· openalex W2753065806 · s2 bc101251
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1244
Durvalumab consolidation therapy produces a significantly higher objective response rate than placebo (28.4% vs. 16.0%; P<0.001) in stage III NSCLC patients following chemoradiotherapy.
0.1449
Durvalumab consolidation therapy after platinum-based chemoradiotherapy significantly improves median progression-free survival (16.8 months vs. 5.6 months; HR 0.52) compared to placebo in patients with unresectable stage III NSCLC who did not progress after chemoradiotherapy.
0.1484
Durvalumab consolidation after chemoradiotherapy in stage III NSCLC significantly prolongs the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months; P<0.001).
0.1730
Durvalumab consolidation after chemoradiotherapy will demonstrate a statistically significant overall survival benefit in the final analysis of the PACIFIC trial in stage III unresectable NSCLC.
0.1901
Grade 3 or 4 treatment-related adverse events occur significantly more frequently with nivolumab plus ipilimumab (55.0%) than with nivolumab monotherapy (16.3%) or ipilimumab monotherapy (27.3%) in untreated metastatic melanoma patients.
0.2086
Pembrolizumab is associated with lower rates of grade 3-5 treatment-related adverse events (10.1–13.3%) compared with ipilimumab (19.9%) in patients with advanced melanoma.